AlphaFold predicted structure
TALDO1 · P37837
Mean pLDDT
95.6/ 100
Very high
337 residues
Confidence breakdown
- Very high(≥ 90)95%
- Confident(70–90)1%
- Low(50–70)2%
- Very low(< 50)3%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
TALDO1
Chr 11p15.5transaldolase 1
- MANE:
- ENST00000319006.8
Annotations refreshed 10 hours ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Diagnostic Grade (Green)
Cholestasis
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalFetal hydrops
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalNeonatal cholestasis
BIALLELIC, autosomal or pseudoautosomalSkeletal dysplasia
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
Disease associations (Open Targets)
transaldolase deficiency
0.80Disorder of carbohydrate metabolism
0.46hydrops fetalis
0.37hereditary disease
0.19microcephaly
0.12Severe global developmental delay
0.12cataract
0.12breast carcinoma
0.10breast cancer
0.09aortic stenosis
0.09
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
Transaldolase
Catalyzes the rate-limiting step of the non-oxidative phase in the pentose phosphate pathway. Catalyzes the reversible conversion of sedoheptulose-7-phosphate and D-glyceraldehyde 3-phosphate into erythrose-4-phosphate and beta-D-fructose 6-phosphate (PubMed:18687684, PubMed:8955144). Not only acts as a pentose phosphate pathway enzyme, but also affects other metabolite pathways by altering its subcellular localization between the nucleus and the cytoplasm (By similarity)